ATE427107T1 - Eine neue verwendung von deferiprone - Google Patents

Eine neue verwendung von deferiprone

Info

Publication number
ATE427107T1
ATE427107T1 AT01949158T AT01949158T ATE427107T1 AT E427107 T1 ATE427107 T1 AT E427107T1 AT 01949158 T AT01949158 T AT 01949158T AT 01949158 T AT01949158 T AT 01949158T AT E427107 T1 ATE427107 T1 AT E427107T1
Authority
AT
Austria
Prior art keywords
deferiprone
patient
new use
cardiac disease
induced cardiac
Prior art date
Application number
AT01949158T
Other languages
English (en)
Inventor
Michael Spino
Antonia Piga
Original Assignee
Apotex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4166629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE427107(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotex Inc filed Critical Apotex Inc
Application granted granted Critical
Publication of ATE427107T1 publication Critical patent/ATE427107T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01949158T 2000-06-30 2001-06-28 Eine neue verwendung von deferiprone ATE427107T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2313270A CA2313270C (en) 2000-06-30 2000-06-30 Use of deferiprone in treating and preventing iron-induced cardiac disease

Publications (1)

Publication Number Publication Date
ATE427107T1 true ATE427107T1 (de) 2009-04-15

Family

ID=4166629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01949158T ATE427107T1 (de) 2000-06-30 2001-06-28 Eine neue verwendung von deferiprone

Country Status (16)

Country Link
US (2) US7049328B2 (de)
EP (1) EP1294379B1 (de)
CN (3) CN1331971A (de)
AT (1) ATE427107T1 (de)
AU (2) AU7040201A (de)
BR (1) BR0112280A (de)
CA (1) CA2313270C (de)
CY (1) CY1109191T1 (de)
DE (1) DE60138189D1 (de)
DK (1) DK1294379T3 (de)
ES (1) ES2324978T3 (de)
HK (1) HK1043316A1 (de)
IL (2) IL153733A0 (de)
PT (1) PT1294379E (de)
WO (1) WO2002002114A1 (de)
ZA (1) ZA200109322B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY151412A (en) * 2006-02-22 2014-05-30 Munnich Arnold The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
CA2681545C (en) 2007-03-28 2013-10-01 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
PL2268282T3 (pl) * 2008-04-25 2015-04-30 Apotex Tech Inc Płynny preparat deferypronu o przyjemnym smaku
ME01911B (me) 2009-07-03 2014-12-20 Apotex Tech Inc Fluorisani derivati 3-hidroksipiridin-4-ona
US9849146B2 (en) 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
US8603814B2 (en) 2009-07-20 2013-12-10 Rutgers The State University Of New Jersey Method of inhibiting nonsense-mediated mRNA decay
BR112014012054A2 (pt) * 2011-11-18 2017-05-30 Apotex Tech Inc métodos de tratamento com deferiprona
WO2016029158A2 (en) * 2014-08-21 2016-02-25 Collaborative Medicinal Development Llc Compositions and methods for extending lifespan
KR102480882B1 (ko) * 2016-08-05 2022-12-26 아브페로 파마슈티칼스, 인크. 금속-매개 상태를 치료하기 위한 투여 요법
CN106983746A (zh) * 2017-03-23 2017-07-28 武汉联合药业有限责任公司 一种药物组合物及其用途
DK3684344T3 (da) 2017-10-25 2025-08-04 Chiesi Farm Spa Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf
AU2020316632B2 (en) * 2019-07-19 2025-09-18 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (TDT)
CN114217071B (zh) * 2021-12-01 2023-11-14 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法铁蛋白胶乳比浊检测试剂盒
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
EP4507679A1 (de) 2022-04-11 2025-02-19 Chiesi Farmaceutici S.p.A. Pharmazeutische formulierungen mit modifizierter freisetzung mit deferipron
CN115429881A (zh) * 2022-09-02 2022-12-06 中国医学科学院基础医学研究所 铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2118176B (en) * 1982-03-24 1985-12-04 Nat Res Dev Pharmaceutical compositions
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor

Also Published As

Publication number Publication date
CN101380322A (zh) 2009-03-11
US20060122273A1 (en) 2006-06-08
CN101933924A (zh) 2011-01-05
AU2001270402B9 (en) 2006-03-02
WO2002002114A1 (en) 2002-01-10
CA2313270A1 (en) 2001-12-30
PT1294379E (pt) 2009-05-04
EP1294379B1 (de) 2009-04-01
EP1294379A1 (de) 2003-03-26
CN101380322B (zh) 2015-06-24
HK1043316A1 (zh) 2002-09-13
AU2001270402B2 (en) 2006-02-02
AU7040201A (en) 2002-01-14
CN1331971A (zh) 2002-01-23
IL153733A0 (en) 2003-07-06
US7049328B2 (en) 2006-05-23
CY1109191T1 (el) 2014-07-02
BR0112280A (pt) 2003-05-13
DK1294379T3 (da) 2009-06-02
ZA200109322B (en) 2002-10-21
ES2324978T3 (es) 2009-08-21
HK1130422A1 (en) 2009-12-31
US20030158234A1 (en) 2003-08-21
DE60138189D1 (de) 2009-05-14
IL153733A (en) 2010-04-29
CA2313270C (en) 2011-09-13

Similar Documents

Publication Publication Date Title
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
GB0225474D0 (en) Therapeutic agents
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
GB0223038D0 (en) Therapeutic compounds
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
ATE190840T1 (de) Zusammensetzung zur behandlung der parkinson- krankheit
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
DE60018085D1 (de) Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
WO2002059346A3 (en) Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
EP1270000A3 (de) Benzoesäure-substituierte Benzopyrane zur Behandlung von Atherosklerose
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
JP2002533400A5 (de)
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
RU2000117402A (ru) Способ лечения микробной экземы
WO2004045505A3 (en) Extract of stephaniae sinica diels and methods of using the same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1294379

Country of ref document: EP